Skip to main content
Clinical Trials/NCT03423004
NCT03423004
Completed
Not Applicable

Comparative Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin

Centre Hospitalier Régional d'Orléans1 site in 1 country9 target enrollmentJanuary 11, 2019
ConditionsPsoriasis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psoriasis
Sponsor
Centre Hospitalier Régional d'Orléans
Enrollment
9
Locations
1
Primary Endpoint
Increase Ratio
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The project topic consists on re-conciliating the fine tuners of the gene expression "microRNAs" and the immunopathogenic occasions responsible for skin disorders in context of skin infection and inflammation such as psoriasis. The skin is a network of effector cells and molecular mediators that constitute a highly sophisticated "Skin Immune System (SIS) described by Jan D Bos in 1986. The cutaneous homeostasis maintenance is dependent on the cross talk between several immune sentinels present in the different compartments of the skin as well as the interplay between innate and adaptive immune responses. The whole is under the control of gene regulation. However, cutaneous homeostasis disruption occurs when the SIS safe framework erroneously sends aggravation signals due to gene regulation disbalance via inflammatory cellular and molecular mediators into the site of infection causing chronic inflammation characterized by thick red irritated skin lesions. The latter was showed to have a characteristic microRNA (regulators of gene expression) signature.

Registry
clinicaltrials.gov
Start Date
January 11, 2019
End Date
July 11, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men or women between 18 and 75
  • Clinical diagnosis of chronic active psoriasis in non-pustular plaque
  • Treated locally with topical corticosteroids

Exclusion Criteria

  • Patient who did not give express consent to participate
  • No affiliation to a social security scheme
  • Patient treated systemically
  • Thrombocytopenic patient
  • Patient known to be HIV-positive
  • Septic patient
  • Patient with only facial lesions
  • Patient with psoriasis with joint involvement
  • Patient participating in another study
  • Patient protected under the law (under guardianship or trusteeship)

Outcomes

Primary Outcomes

Increase Ratio

Time Frame: Day 0

Increase ratio between relative expression of different genes (miR-21 and InterLeukin-22) of psoriatic lesional skin and non-psoriatic skin

Secondary Outcomes

  • Correlation between Psoriasis Area Severity Index and miR-21 expression(Day 0)

Study Sites (1)

Loading locations...

Similar Trials